Book a demo

Cut patent&paper research from weeks to hours with PatSnap Eureka AI!

Try now

NMIBC Drug Pipeline: Immunotherapy & Gene Therapy — PatSnap Eureka

NMIBC Drug Pipeline: Immunotherapy & Gene Therapy — PatSnap Eureka
NMIBC Drug Pipeline

Non-Muscle Invasive Bladder Cancer: Intravesical Immunotherapy, Gene Therapy & Targeted Approaches

NMIBC represents 70–80% of all new bladder cancer diagnoses. With BCG failure affecting up to 40% of patients, a new wave of intravesical immunotherapy, oncolytic virotherapy, ADC delivery, and FGFR-targeted agents is reshaping the pipeline. Explore the patent intelligence behind it.

NMIBC Substage Distribution
Ta papillary disease dominates at ~70% of NMIBC cases; T1 ~20%; CIS ~10%
NMIBC Substage Distribution: Ta (Papillary) 70%, T1 (Lamina Propria) 20%, CIS (Carcinoma in Situ) 10% Distribution of NMIBC pathological substages based on patent literature. Papillary Ta disease accounts for approximately 70% of NMIBC, T1 for 20%, and CIS for 10%, as reported in multiple Agensys patent filings analyzed via PatSnap Eureka. NMIBC Substages Ta — 70% T1 — 20% CIS — 10%
70–80%
of all new bladder cancer cases are NMIBC
40%
of NMIBC patients experience BCG failure
30–85%
recurrence rate after standard TURBT + BCG
8+
distinct patent filings each from TARIS & Agensys
Disease & Target Overview

The Unmet Need Driving NMIBC Pipeline Innovation

Non-muscle invasive bladder cancer (NMIBC) encompasses three pathological substages: pTa (non-invasive papillary urothelial carcinoma), pT1 (lamina propria invasion), and pTis (carcinoma in situ, CIS). Intravesical BCG immunotherapy remains the standard adjuvant after TURBT for high-risk NMIBC, yet up to 40% of patients experience BCG failure — creating a well-defined and commercially significant unmet need that motivates most pipeline innovation.

The field is at an inflection point, driven by BCG shortages, a substantial BCG-unresponsive or BCG-refractory patient population, and a near-absence of approved second-line intravesical options. This has accelerated innovation across immune checkpoint modulation, oncolytic virotherapy, ADC-based intravesical delivery, FGFR-targeted small molecules, and mycobacterial immunotherapeutics.

The PD-L1/PD-1 axis is the single most represented target across the patent dataset, addressed by MedImmune, Genentech/Roche, AstraZeneca, and Foundation Medicine. PD-L1 is reported to be expressed in 12% of bladder tumor cells and up to 50% of malignant urothelial cells within carcinoma in situ. Other key targets include Nectin-4 (191P4D12), EpCAM, FGFR3, CDCP1, LAG3/TIGIT, and long non-coding RNA (lncRNA) for genomic subtyping. Explore the full target landscape with PatSnap IP analytics.

~70%
Ta papillary disease among NMIBC substages
~20%
T1 lamina propria invasion substage
~10%
Carcinoma in situ (CIS) substage
50%
PD-L1 expression in malignant urothelial cells in CIS
Key Molecular Targets
  • PD-L1 / PD-1 axis (most cited)
  • Nectin-4 / 191P4D12 (ADC target)
  • EpCAM (bispecific & immunoconjugate)
  • FGFR3 (driver mutation in NMIBC)
  • CDCP1 (radioimmunotherapy, 2024)
  • LAG3 / TIGIT (emerging checkpoints)
  • lncRNA (genomic subtyping)
Patent Intelligence

NMIBC Pipeline: Patent Activity by Modality & Assignee

Patent filing patterns reveal where commercial and clinical investment is concentrated across the NMIBC therapeutic landscape.

Patent Filings by Therapeutic Modality

TARIS Biomedical and Agensys lead with 8+ filings each; CG Oncology's 2025 filings signal active clinical-stage activity

NMIBC Patent Filings by Modality: Intravesical Gemcitabine (TARIS) 8+, Nectin-4 ADC (Agensys) 8+, CD3xEpCAM Bispecific (Lindhofer) 4+, Oncolytic Virus (CG Oncology) 2, FGFR Inhibitors (Janssen) 2, Recombinant Mycobacterium (Serum Life Science) 1 Horizontal bar chart showing relative patent filing counts per NMIBC therapeutic modality based on PatSnap Eureka dataset analysis. Intravesical gemcitabine and Nectin-4 ADC approaches have the broadest IP coverage, while oncolytic virus filings from 2025 indicate recent clinical activity. Gemcitabine (TARIS) 8+ Nectin-4 ADC (Agensys) 8+ CD3×EpCAM (Lindhofer) 4+ Oncolytic Virus (CG Oncology) 2 FGFR Inhibitors (Janssen) 2 Recomb. Mycobacterium 1 0 4 8+ Number of patent filings (approximate)

Jurisdictional Coverage by Top NMIBC Assignees

Global patent coverage signals commercial intent; TARIS and Agensys hold the broadest multi-jurisdictional portfolios

NMIBC Jurisdictional Coverage: TARIS Biomedical (SG, IL, AU, JP, WO), Agensys (WO, US, CA, TW, JP, CN, AU), Lindhofer (WO, CA, AU, JP), Genentech/Roche (JP, MX, CN, WO), MedImmune/AZ (SG, IL), CG Oncology (WO 2025) Bubble chart representing jurisdictional spread of NMIBC patent filings by assignee, derived from PatSnap Eureka patent data. Larger bubbles indicate broader multi-jurisdictional IP coverage, with TARIS and Agensys showing the widest geographic protection strategies. TARIS SG·IL·AU·JP·WO Agensys WO·US·CA·TW·JP·CN·AU Lindhofer WO·CA·AU·JP Genentech/ Roche MedImmune SG·IL CG Onco WO 2025 Bubble size ∝ number of jurisdictions covered

Dig deeper into NMIBC patent landscapes, assignee portfolios, and filing timelines

Run Your NMIBC Patent Search on Eureka
Therapeutic Modalities

Eight Innovation Tracks in the NMIBC Drug Pipeline

Patent and literature signals across intravesical immunotherapy, oncolytic virotherapy, ADCs, FGFR inhibitors, multispecific antibodies, and genomic subtyping strategies.

Modality 01 · Immunotherapy

Intravesical BCG & Next-Generation Mycobacterial Immunotherapy

Standard intravesical BCG remains the reference background for virtually all NMIBC innovation. Serum Life Science Europe GmbH (Canada, 2023) has filed a patent disclosing a recombinant Mycobacterium cell engineered for use specifically in second-line NMIBC therapy following BCG failure, positioning it as a clinically actionable successor to standard BCG.

Patent-only · Early translational stage
Modality 02 · Oncolytic Virotherapy

Intravesical Oncolytic Virotherapy (CG Oncology & Istari)

CG Oncology, Inc. (WO, 2025) discloses intravesical administration of cretostimogene grenadenorepvec (an oncolytic adenovirus) for NMIBC, alone or combined with immune checkpoint modulators or chemotherapy. Istari Oncology (WO, 2023) adds a mechanistically distinct chimeric poliovirus (Sabin type I/HRV2 IRES) in a structured induction + maintenance regimen. Priority applications from 2022–2025 suggest IND-enabling or early clinical stages.

WO 2025 filings · Active clinical program signals
Modality 03 · ADC Delivery

ADC-Based Intravesical Therapy (Nectin-4 / EpCAM / HER2)

Agensys, Inc. holds an extensive multi-jurisdictional family (WO, US, CA, TW, JP, CN, AU) covering intravesical anti-Nectin-4 ADC (191P4D12) for BCG-unresponsive NMIBC. Viventia Biosciences (CN) discloses EpCAM-targeted immunoconjugates with induction and maintenance dosing. This represents a conceptually novel direction: applying ADC technology via intravesical instillation to achieve local cytotoxicity while potentially limiting systemic exposure. Learn more about ADC pipeline intelligence.

Multi-jurisdictional · BCG-unresponsive population
Modality 04 · Targeted Therapy

FGFR Tyrosine Kinase Inhibitors (Janssen Pharmaceutica)

Janssen Pharmaceutica NV (WO/IL, 2021–2022) holds the most NMIBC-specific targeted therapy filings for FGFR inhibition in HR-NMIBC and IR-NMIBC. FGFR3 is identified as a driver mutation in a significant fraction of NMIBC tumors. A complementary patent from Institut François Radvanyi (US, 2013) addresses CDKN2A as a predictive biomarker in FGFR3-mutant NMIBC, defining a precision oncology subpopulation. Track FGFR patent activity via PatSnap analytics.

HR-NMIBC & IR-NMIBC specific · CDKN2A co-mutation marker
Modality 05 · Sustained-Release Delivery

Continuous Intravesical Gemcitabine Delivery (TARIS Biomedical)

TARIS Biomedical LLC is the most prolific single assignee in this dataset with at least 8 distinct filings spanning SG, IL, AU, JP, and WO jurisdictions. Their sustained-release intravesical device delivers continuous gemcitabine for BCG-refractory and BCG-naive HR-NMIBC. The most recent WO 2026 filing (priority from September–October 2024 provisionals) indicates a clinical dataset likely supports specific BCG-naive HR-NMIBC claims.

8+ filings · WO 2026 most recent · Clinical-stage signals
Modality 06 · Bispecific Antibody

CD3 × EpCAM Multispecific Antibodies (Horst Lindhofer)

Horst Lindhofer holds a family of patents (WO, CA, AU, JP) for CD3 × EpCAM bispecific antibodies administered intravesically for NMIBC and other urinary tract neoplasms. The mechanism relies on T-cell redirection to EpCAM-expressing urothelial tumor cells within the bladder lumen. Retrieved Japanese patent text explicitly states PD-L1 is expressed in up to 50% of malignant urothelial cells and situates BCG as the main current option, highlighting the therapeutic gap being addressed.

Active legal status multiple jurisdictions · Commercial intent
Modality 07 · Checkpoint Blockade

Intravesical PD-1/PD-L1 Checkpoint Blockade (Photocure ASA)

Photocure ASA has filed Chinese patents describing intravesical instillation of anti-PD-L1 and/or anti-PD-1 antibodies as neoadjuvant therapy for high-risk NMIBC patients scheduled for cystectomy, including patients with multiply recurrent high-grade tumors or CIS. This is mechanistically distinct from systemic checkpoint inhibition and specifically addresses the intravesical delivery route for immune checkpoint blockade. NIH clinical trial databases provide complementary clinical context.

CN 2018 patent · Active status · Preclinical–translational
Modality 08 · Cytokine Immunotherapy

IL-2 Fusion Protein–Based Immunotherapy (Altor BioScience)

Altor BioScience Corporation discloses IL-2 fusion protein combinations with one or more therapeutic agents for bladder cancer treatment (US, 2015; AU, 2018). Retrieved text specifically notes that bladder cancer has been well-characterized at the molecular level but has a historical paucity of successful clinical trials with molecular targeted agents, providing rationale for cytokine-based immunotherapy as an alternative approach.

US & AU patents · Development stage not explicitly stated
PatSnap Eureka

Map the Full NMIBC Competitive Patent Landscape

Identify white spaces, track assignee activity, and monitor new filings across all eight NMIBC modalities in real time.

Start Your NMIBC Landscape Analysis
Combination & Emerging Directions

Convergent Combination Strategies in NMIBC

Patent signals reveal several convergent strategies combining intravesical immunostimulation with systemic or locoregional checkpoint modulation.

🦠

Oncolytic Virus + Immune Checkpoint Modulator

Both CG Oncology WO 2025 filings explicitly claim combinations of intravesical cretostimogene grenadenorepvec with immune checkpoint modulators or chemotherapy. The Cold Genesys JP patent (2019) describes a Phase I/II study combining intravesical CG0070 with intravesical CTLA-4 inhibition and systemic OX40 agonist, measuring PD-L1/PD-1 changes as primary efficacy endpoints. Intravesical immunostimulation + checkpoint modulation is an emerging paradigm.

💊

Intravesical Gemcitabine + Immunomodulating Agent

Multiple TARIS Biomedical filings (SG 2018, IL 2022, AU 2023) claim co-administration of gemcitabine with an immunomodulating agent for lower tract urothelial carcinoma. Retrieved JP text from TARIS explicitly notes that local gemcitabine can modulate the tumor microenvironment immune response, induce systemic immunity, and trigger antigen presentation — providing mechanistic rationale for this combination approach.

🎯

PD-1 × LAG3 Bispecific + Anti-TIGIT (Roche WO 2024)

The Roche WO 2024 filing is the most recent multi-checkpoint combination patent in this dataset, combining a PD-1/LAG3 bispecific antibody with an anti-TIGIT antagonist antibody for urothelial bladder cancer treatment. This signals movement toward dual or triple checkpoint co-inhibition beyond standard PD-1/PD-L1 monotherapy, with LAG3 and TIGIT as the next-generation co-inhibitory targets.

🔬

Biomarker-Guided Oncolytic Therapy (CG Oncology 2025)

The CG Oncology biomarker-guided WO 2025 patent explicitly incorporates predictive biomarker selection into oncolytic virus therapy protocols, signaling convergence of companion diagnostics with intravesical immunotherapy. The AstraZeneca patent also introduces blood-based mutational burden and circulating tumor DNA (ctDNA) mutations as biomarkers for sensitivity to durvalumab, extending biomarker-guided selection to NMIBC contexts.

🔒
Unlock 2 More Combination Strategies
Access full analysis of ADC intravesical + BCG failure population targeting and HAL-guided photodynamic + checkpoint blockade combinations.
ADC + BCG-failure definition HAL + anti-PD-L1 + patent links
Explore Full Combinations on Eureka →
Assignee & Author Landscape

Key Organizations in the NMIBC Patent Dataset

Patent activity strongly dominates over academic literature. Innovation is primarily commercial and IP-driven, with university contributions focused on subtyping and biomarker identification.

Assignee Modality Focus Jurisdictions Filing Recency Stage Signal
TARIS Biomedical LLC Intravesical Gemcitabine SG, IL, AU, JP, WO WO 2026 (most recent) Clinical-stage
Agensys, Inc. (Astellas) Nectin-4 ADC WO, US, CA, TW, JP, CN, AU US 2025 (pending) Active clinical dev.
Horst Lindhofer CD3×EpCAM Bispecific WO, CA, AU, JP JP 2023 Active IP protection
MedImmune / AstraZeneca Anti-PD-L1 (durvalumab) SG, IL Multiple active Clinical-stage
Genentech / F. Hoffmann-La Roche Atezolizumab / PD-1×LAG3 JP, MX, CN, WO WO 2024 Clinical-stage
Janssen Pharmaceutica NV FGFR Inhibitors WO, IL 2021–2022 Translational/clinical
CG Oncology, Inc. Oncolytic Adenovirus WO WO 2025 (most recent) Clinical readout signal
Istari Oncology, Inc. Chimeric Poliovirus WO WO 2023 IND-enabling stage

Track Every NMIBC Assignee's Filing Activity

Monitor new patents, jurisdictional expansions, and competitive moves across the full NMIBC landscape with PatSnap Eureka.

Monitor NMIBC Assignees on Eureka
Clinical & Translational Signals

Clinical Evidence Embedded in NMIBC Patent Filings

Multiple Agensys NMIBC filings (WO 2023, US 2025) explicitly identify BCG-unresponsive disease as a defined clinical subpopulation, suggesting alignment with FDA regulatory guidance frameworks. Retrieved filings describe radical cystectomy as the remaining option for BCG-non-responders, motivating bladder-preserving intravesical ADC development.

The Agensys MIBC ADC WO 2023 filing cites the ABACUS Phase II study (Powles et al., 2018), reporting 29% pathological complete response (pCR) with neoadjuvant atezolizumab in cisplatin-ineligible MIBC patients, with pCR rising to 40% in PD-L1-positive patients. Genentech/Roche JP patents (2023) reference the IMvigor011 Phase III double-blind randomized trial of adjuvant atezolizumab vs. placebo in ctDNA-positive high-risk MIBC post-cystectomy.

Kyushu University (EP 2022, US 2022) has filed patents for SNP-based prediction of BCG intravesical therapy resistance and relapse, representing translational tools to prospectively identify BCG-refractory patients before treatment. The European Patent Office EP filing confirms international translational intent. Track biomarker patent development via PatSnap analytics.

The TARIS Biomedical WO 2026 filing claims priority from provisional applications filed in September and October 2024, indicating a clinical dataset is likely supporting specific claims about BCG-naive HR-NMIBC. CG Oncology WO 2025 filings claim priority from provisional applications filed in May 2024 and April 2025, consistent with an active clinical program generating data at the time of filing.

Key Clinical Signals
  • ABACUS Phase II: 29% pCR with atezolizumab; 40% in PD-L1+ patients
  • IMvigor011 Phase III: adjuvant atezolizumab vs. placebo in ctDNA+ MIBC
  • BCG-unresponsive NMIBC defined as regulatory-relevant endpoint
  • Kyushu University SNP biomarkers for BCG resistance prediction
  • TARIS WO 2026: BCG-naive HR-NMIBC clinical data package signal
  • CG Oncology 2025: active clinical program data generation signal
29% → 40%
pCR with atezolizumab in ABACUS Phase II; rises to 40% in PD-L1-positive patients
Frequently asked questions

NMIBC Drug Pipeline — Key Questions Answered

Still have questions about the NMIBC pipeline? Let PatSnap Eureka answer them for you.

Ask PatSnap Eureka About NMIBC Patents
PatSnap Eureka

Accelerate Your NMIBC Drug Discovery & IP Strategy

Join 18,000+ innovators already using PatSnap Eureka to track the NMIBC pipeline, identify BCG-failure unmet needs, and monitor competitive patent activity across intravesical immunotherapy, ADCs, and targeted therapies.

References

  1. Recombinant Mycobacterium as an Immunotherapeutic Agent for the Second-Line Therapy of Bladder Carcinoma — Serum Life Science Europe GmbH, CA 2023
  2. Methods of Treating Bladder Cancer Using an Oncolytic Virus — CG Oncology, Inc., WO 2025
  3. Methods and Compositions for Biomarker-Guided Bladder Cancer Therapy — CG Oncology, Inc., WO 2025
  4. Methods for Treating Bladder Cancers by Intravesical Instillation of a Chimeric Poliovirus — Istari Oncology, Inc., WO 2023
  5. Methods for Treating NMIBC with ADC that Bind to 191P4D12 Proteins — Agensys, Inc., WO 2023
  6. Methods for Treating NMIBC with ADC that Bind to 191P4D12 Proteins — Agensys, Inc., US 2025
  7. Methods for Treating EpCAM-Positive Bladder Cancer — Viventia Biosciences Inc., CN 2018
  8. FGFR Tyrosine Kinase Inhibitors for the Treatment of High-Risk NMIBC — Janssen Pharmaceutica NV, IL 2022
  9. CDKN2A as a Prognostic Marker in Bladder Cancer — Radvanyi, François, US 2013
  10. Methods of Treating High-Risk NMIBC Unresponsive to BCG Therapy — TARIS Biomedical LLC, WO 2025
  11. Intravesical Gemcitabine for Use in Treating BCG-Naive HR-NMIBC — TARIS Biomedical LLC, WO 2026
  12. Multispecific Antibodies for Use in the Treatment of a Neoplasm of the Urinary Tract — Lindhofer, Horst, WO 2017
  13. Intravesical Treatment for Bladder Cancer — Photocure ASA, CN 2018
  14. Methods for Treating Neoplasia (IL-2 Fusion Protein) — Altor BioScience Corporation, US 2015
  15. Treatment of Bladder Cancer with Radiolabeled Antibodies Targeting CDCP1 — The Regents of the University of California, US 2024
  16. Methods and Compositions for Treating Urothelial Bladder Cancer — F. Hoffmann-La Roche AG, WO 2024
  17. Biomarker for Predicting Therapeutic Effects of BCG Intravesical Therapy — Kyushu University, US 2022
  18. Methods of Treating Solid or Lymphoid Tumors with Combination Therapy — Cold Genesys, Inc., JP 2019
  19. World Health Organization — Cancer Classification and Bladder Cancer Epidemiology
  20. National Institutes of Health — Bladder Cancer Clinical Trial Registry
  21. U.S. Food and Drug Administration — BCG-Unresponsive NMIBC Regulatory Guidance
  22. European Patent Office — NMIBC Patent Database

All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.

Ask PatSnap Eureka
Ask PatSnap Eureka
AI innovation intelligence · always on
Ask anything about the NMIBC drug pipeline.
PatSnap Eureka searches patents and research to answer instantly.
Try asking
Powered by PatSnap Eureka